Acute lymphatic leukemia (ALL)
- The allopathic definition:
Malignant degeneration and dysmaturity of white blood cells. Here the body produces immature white blood corpuscles (lymphocytes), the so-called blasts.
- How frequently does ALL occur (incidence rate) in Germany (USA appr. x 3)?
Currently one per 100,000 people.
L-1, l-2, and l-3 blasts are differentiated morphologically. L-1 blasts are small and have a homogenous nucleus. Approximately 20% of all blasts have a large nucleus with indentations and in general they are heterogeneous (different types). L-3 blasts are all large and homogenous (same type).
- How is ALL diagnosed by allopathic practitioners?
Fatigue, fever, subcutaneous bleeding (ecchymosis), paleness, bone pain, general neurological symptoms, joint pain. Bone marrow punction, (blast count higher than 25%), blood tests (leucocytes, Hb, thrombocytes, measuring the size of the liver and spleen, testicular examination, ultrasound, CT. Basically every physician should make a precise differential diagnosis of rheumatic disease or of an osteomyelitis (bone marrow infection). In detail such a diagnosis should also be made of neuroblastomas, rhabdomysarcomas, and naturally lymphomas. Cytogenetic changes of individual chromosomes are evident for approximately 50% of the patients. The translocation of the cABL protooncogene (paternal chromosome 9q34) designated as “Philadelphia chromosome” and the BCR (Breakdown Cluster Region/maternal chromosome 22q11) is present in 4% of the incidences of childhood ALL, and 20% of the incidences of adult ALL. Stages: As opposed to solid tumors, there is no stage subdivision for acute lymphatic leukemia. The type of treatment depends on the age of the patient, the patient’s hemogram, and whether the patient is undergoing the first, second, or third therapy. Otherwise the groups are divided the same way they are divided for AML, in induction therapy, consolidation phase, maintenance therapy, and recrudescence therapies (see AML for more detailed information).
What are the allopathic therapy concepts?
In general the treatment protocol for ALL prescribes that chemotherapy will be administered in different blocks in as high a dose as possible over a 6-month period, followed by an additional two years of lower-dose chemotherapy. Usually the following toxins are used: Ara-C, daunorubicin, cyclophosphamide, asparaginase, vincristine, prednisone, mercaptopurine and methotrexate.
There is no doubt that there are studies that seem to speak for a chemotherapy. Careful reading however reveals that almost all studies compare old chemotherapy protocols with those that are more recent. Again we do not know what these protocols would look like in comparison with holistic therapies.
Bone marrow therapies (BMT)
In recent years bone marrow substitution therapies in particular have become more and more of a standard; for instance:
A. Allogenic bone marrow transplant / stem cell transplant:
Here the patient receives stem cells from a donor. First high doses of chemotherapy are administered with or without supplemental radiation, in order to destroy all the bone marrow in the body. Then healthy bone marrow is taken from a different donor. The donor’s healthy bone marrow is then injected into the patient, and this is supposed to replace the patient’s destroyed bone marrow.
B. Autologic bone marrow transplant / stem cell transplant:
In this therapy bone marrow / stem cells are removed from the patient, then the bone marrow is treated with medication to kill all cancer cells, and after high-dose chemotherapy it is returned to the patient. The bone marrow is frozen for storage. The patient then receives a high-dose chemotherapy with or without supplemental radiation therapy to destroy all the remaining bone marrow. The stored, frozen bone marrow is thawed and then injected back into the patient.
Naturally one should not forget that bone marrow transplant involves a high risk of the patient dying due to the therapy. Neither of these therapies is undisputed, even among allopathic practitioners.
Radiation therapy, usually with 24-26 Gy, is recommended for patients, particularly in the case of mediastinal tumors.
Additional therapies like hormones, antibodies, etc.
Although there are approaches with interferon, other therapies like cytokine therapies or monoclonal antibodies, are not used for ALL, because next to testicular cancer and AML, ALL is considered to be the stronghold of chemotherapies.
Please read the additional information listed under AML. Even if the individual protocols are different, the therapy approach for AML and ALL are identical.